Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study

CONCLUSIONS: TACE plus pembrolizumab was tolerable with no evidence of synergistic toxicity, encouraging further clinical development of immunotherapy alongside TACE.PMID:38578610 | DOI:10.1158/1078-0432.CCR-24-0177

Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: David J Pinato Antonio D'Alessio Claudia Angela Maria Fulgenzi Alexandra Emilia Schlaak Ciro Celsa Saskia Killmer Jesus Miguens Blanco Caroline Ward Charalampos-Vlasios Stikas Mark R Openshaw Nicole Acuti Georgios Nteliopoulos Cristina Balcells Hector C K Source Type: research